Ranbaxy's First Biosimilar Target Will Be Amgen's Neupogen
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories is set to venture into biosimilar development, targeting Amgen's neutropenia treatment Neupogen (filgrastim) as its first generic biologic, the company announced Feb. 7
You may also be interested in...
Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007
Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.
Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.
Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.
Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval
Sandoz' follow-on human growth hormone does not establish a precedent for follow-on proteins for biologics regulated under the Public Health Service Act.